To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Specifications
- Antibody type:Primary
- Antigen name:VEGF RTH258 scFv
- Clonality:Recombinant
- Clone:Abz5
- Gene ID:7422
- Isotype:IgG1
- Reactivity:Human
- Antigen symbol:VEGF-A
- Conjugation:Unconjugated
- ELISA:Yes
- Flow cytometry:Yes
- Size:50 µg
- Western blot:Yes
- Form:Liquid
- Antigen synonyms:RTH258|VEGFA|Anti-VEGF-A Antibody|Vascular permeability factor|VPF|Vascular endothelial growth factor A|Brolucizumab|VEGF A
- Storage buffer:PBS, pH 7.2, 30% glycerol.
- Storage temperature:Store at 2…8 °C
- Shipping temperature:Wet Ice
- Cat. no.:CA76539-400
- Packaging:Vial
Specifications
About this item
Humanized Recombinant Anti-VEGFA ScFV fragment Antibody has been tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured VEGF-A and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user
- Expressed in CHO cells
- >90% pure by SDS-PAGE analysis
- Tested for use in Flow Cytometry, Western Blot, and ELISA
VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21% and 24% respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator; it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Antibody against VEGF-A (Bevacizumab or brand name Avastin) is approved for treatment of cancer by inhibiting angiogenesis. Ranibizumab, a Fab fragment of Avastin or so-called Lucentis is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This antibody has its amino acid sequence like one of Brolucizumab (sold under trade names Beovu or Vsiqq) - a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).